2024年12月11日 · <p>EY&#39;s Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.</p>

Life Science Leader - thought leadership articles and discussions about the current life science industry

2024年10月28日 · This presentation highlights key pharmaceutical launches anticipated in 2025, emphasizing their potential to address unmet needs across various medical fields. The document covers new developments in oncology, neurology, infectious diseases, cardiovascular conditions, and autoimmune disorders. These drugs represent advancements in treatment paradigms, market-changing opportunities, and ...

2024年11月19日 · By Louise Modis, Ph.D. Louise Modis, Ph.D. Imagine a gem hunter facing a vast and uncharted landscape to uncover a single beautiful diamond. It is a bit like drug discovery. Scientists create and evaluate hundreds and thousands of molecules in their relentless pursuit of a transformative discovery that could revolutionize health. It is this pursuit that drives me. If we want to discover a ...

2024年12月4日 · <p>Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal needs, and the personal needs of others, in navigating a professional career.</p>

2024年10月3日 · An LLC model in biotech offers advantages like streamlined deal-making, IP ownership, and capital reinvestment, but also comes with specific risks.

2024年12月23日 · <p>Where are legislative trends pointing on biopharmaceutical patents? Sona De, a partner at Sidley, reviews existing proposals and offers thoughts on what&#39;s to come in 2025.</p>

2024年10月18日 · <p>Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer&#39;s disease, schizophrenia, glaucoma, and Fragile X syndrome.</p>

2024年11月21日 · <p>Megan Chacon, a principal at Fish &amp; Richardson and a member of the firm&rsquo;s life sciences industry team, answers questions about what a second Trump administration could mean for biopharmaceutical IP and drug patents.</p>

2024年10月4日 · <p>Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.</p>